About legend biotech - LEGN
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.
LEGN At a Glance
Legend Biotech Corp.
2101 Cottontail Lane
Somerset, New Jersey 08873
| Phone | 1-737-317-5050 | Revenue | 627.56M | |
| Industry | Pharmaceuticals: Major | Net Income | -177,114,792.39 | |
| Sector | Health Technology | 2024 Sales Growth | 120.085% | |
| Fiscal Year-end | 12 / 2025 | Employees | 2,609 | |
| View SEC Filings |
LEGN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.481 |
| Price to Book Ratio | 5.743 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -18.082 |
| Enterprise Value to Sales | 8.251 |
| Total Debt to Enterprise Value | 0.068 |
LEGN Efficiency
| Revenue/Employee | 240,534.922 |
| Income Per Employee | -67,886.084 |
| Receivables Turnover | 5.025 |
| Total Asset Turnover | 0.357 |
LEGN Liquidity
| Current Ratio | 4.624 |
| Quick Ratio | 4.538 |
| Cash Ratio | 4.044 |
LEGN Profitability
| Gross Margin | 58.877 |
| Operating Margin | -49.354 |
| Pretax Margin | -25.211 |
| Net Margin | -28.223 |
| Return on Assets | -10.067 |
| Return on Equity | -15.456 |
| Return on Total Capital | -12.732 |
| Return on Invested Capital | -11.954 |
LEGN Capital Structure
| Total Debt to Total Equity | 33.694 |
| Total Debt to Total Capital | 25.202 |
| Total Debt to Total Assets | 20.992 |
| Long-Term Debt to Equity | 33.233 |
| Long-Term Debt to Total Capital | 24.858 |